149 related articles for article (PubMed ID: 21062998)
1. Six-month results of the NEVO Res-Elution I (NEVO RES-I) trial: a randomized, multicenter comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions.
Ormiston JA; Abizaid A; Spertus J; Fajadet J; Mauri L; Schofer J; Verheye S; Dens J; Thuesen L; Dubois C; Hoffmann R; Wijns W; Fitzgerald PJ; Popma JJ; Macours N; Cebrian A; Stoll HP; Rogers C; Spaulding C;
Circ Cardiovasc Interv; 2010 Dec; 3(6):556-64. PubMed ID: 21062998
[TBL] [Abstract][Full Text] [Related]
2. Intravascular ultrasound results from the NEVO ResElution-I trial: a randomized, blinded comparison of sirolimus-eluting NEVO stents with paclitaxel-eluting TAXUS Liberté stents in de novo native coronary artery lesions.
Otake H; Honda Y; Courtney BK; Shimohama T; Ako J; Waseda K; Macours N; Rogers C; Popma JJ; Abizaid A; Ormiston JA; Spaulding C; Cohen SA; Fitzgerald PJ
Circ Cardiovasc Interv; 2011 Apr; 4(2):146-54. PubMed ID: 21386089
[TBL] [Abstract][Full Text] [Related]
3. A multicenter randomized trial comparing amphilimus- with paclitaxel-eluting stents in de novo native coronary artery lesions.
Carrié D; Berland J; Verheye S; Hauptmann KE; Vrolix M; Violini R; Dibie A; Berti S; Maupas E; Antoniucci D; Schofer J
J Am Coll Cardiol; 2012 Apr; 59(15):1371-6. PubMed ID: 22284328
[TBL] [Abstract][Full Text] [Related]
4. Two-year follow-up of the NEVO ResElution-I(NEVO RES-I) trial: a randomised, multicentre comparison of the NEVO sirolimus-eluting coronary stent with the TAXUS Liberté paclitaxel-eluting stent in de novo native coronary artery lesions.
Abizaid A; Ormiston JA; Fajadet J; Mauri L; Schofer J; Verheye S; Dens J; Thuesen L; Macours N; Qureshi AC; Spaulding C;
EuroIntervention; 2013 Oct; 9(6):721-9. PubMed ID: 23518218
[TBL] [Abstract][Full Text] [Related]
5. First nine-month complete invasive assessment (angiography, IVUS, and OCT) of the novel NEVO sirolimus-eluting stent with biodegradable polymer.
Abizaid A; Costa JR; Feres F
Catheter Cardiovasc Interv; 2011 Jan; 77(1):49-51. PubMed ID: 20506126
[TBL] [Abstract][Full Text] [Related]
6. Recent progress in percutaneous coronary intervention: evolution of the drug-eluting stents, focus on the XIENCE V drug-eluting stent.
Doostzadeh J; Clark LN; Bezenek S; Pierson W; Sood PR; Sudhir K
Coron Artery Dis; 2010 Jan; 21(1):46-56. PubMed ID: 19952925
[TBL] [Abstract][Full Text] [Related]
7. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
[TBL] [Abstract][Full Text] [Related]
8. Comparison of sirolimus-eluting stent, paclitaxel-eluting stent, and bare metal stent in the treatment of long coronary lesions.
Kim YH; Park SW; Lee CW; Hong MK; Gwon HC; Jang Y; Lee MM; Koo BK; Oh DJ; Seung KB; Tahk SJ; Yoon J; Park SJ
Catheter Cardiovasc Interv; 2006 Feb; 67(2):181-7. PubMed ID: 16400663
[TBL] [Abstract][Full Text] [Related]
9. Head-to-head comparison of sirolimus- and paclitaxel-eluting stent in the same diabetic patient with multiple coronary artery lesions: a prospective, randomized, multicenter study.
Tomai F; Reimers B; De Luca L; Galassi AR; Gaspardone A; Ghini AS; Ferrero V; Favero L; Gioffrè G; Prati F; Tamburino C; Ribichini F
Diabetes Care; 2008 Jan; 31(1):15-9. PubMed ID: 17909090
[TBL] [Abstract][Full Text] [Related]
10. Comparison of dual drug-eluting Cilotax stent and paclitaxel-eluting Taxus Liberte stent in native coronary artery lesions.
Lee CW; Park DW; Seung KB; Kim PJ; Park HJ; Kim WJ; Lee JY; Kang SJ; Lee SH; Kim YH; Park SW; Park SJ
Am J Cardiol; 2011 Apr; 107(7):990-4. PubMed ID: 21296317
[TBL] [Abstract][Full Text] [Related]
11. Sirolimus, Tacrolimus and Zotarolimus eluting stents to treat bifurcated lesions: a 7-month clinical outcome comparison.
Brugaletta S; Burzotta F; Trani C; Todaro D; Talarico G; Porto I; Leone AM; Niccoli G; Mazzari MA; Mongiardo R; Schiavoni G; Crea F
Minerva Cardioangiol; 2008 Feb; 56(1):35-42. PubMed ID: 18432167
[TBL] [Abstract][Full Text] [Related]
12. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial.
Park DW; Kim YH; Yun SC; Kang SJ; Lee SW; Lee CW; Park SW; Seong IW; Lee JH; Tahk SJ; Jeong MH; Jang Y; Cheong SS; Yang JY; Lim DS; Seung KB; Chae JK; Hur SH; Lee SG; Yoon J; Lee NH; Choi YJ; Kim HS; Kim KS; Kim HS; Hong TJ; Park HS; Park SJ
J Am Coll Cardiol; 2010 Oct; 56(15):1187-95. PubMed ID: 20883925
[TBL] [Abstract][Full Text] [Related]
13. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice.
Dawkins KD; Grube E; Guagliumi G; Banning AP; Zmudka K; Colombo A; Thuesen L; Hauptman K; Marco J; Wijns W; Popma JJ; Koglin J; Russell ME;
Circulation; 2005 Nov; 112(21):3306-13. PubMed ID: 16286586
[TBL] [Abstract][Full Text] [Related]
14. Firebird and cypher sirolimus-eluting stents and bare metal stents in treatment of very long coronary lesions.
Fan L; Chen LL; Lin CG; Peng YF; Zheng XC; Luo YK; Zhang FL; Chen JH; Yan XP; Huang ZR
Chin Med J (Engl); 2008 Aug; 121(16):1518-23. PubMed ID: 18982862
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
[TBL] [Abstract][Full Text] [Related]
16. Final 5-year results of the TAXUS II trial: a randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for de novo coronary artery lesions.
Silber S; Colombo A; Banning AP; Hauptmann K; Drzewiecki J; Grube E; Dudek D; Baim DS
Circulation; 2009 Oct; 120(15):1498-504. PubMed ID: 19786634
[TBL] [Abstract][Full Text] [Related]
17. Nevo stent: a successful stent makeover.
Belardi JA
Catheter Cardiovasc Interv; 2011 Jan; 77(1):52-3. PubMed ID: 21181969
[No Abstract] [Full Text] [Related]
18. Three-year outcomes following sirolimus- versus paclitaxel-eluting stent implantation in an unselected population with coronary artery disease (from the REWARDS Registry).
Hanna NN; Gaglia MA; Torguson R; Ben-Dor I; Gonzalez MA; Collins SD; Syed AI; Maluenda G; Kaneshige K; Xue Z; Satler LF; Kent KM; Suddath WO; Pichard AD; Waksman R
Am J Cardiol; 2010 Aug; 106(4):504-10. PubMed ID: 20691308
[TBL] [Abstract][Full Text] [Related]
19. Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization.
Windecker S; Remondino A; Eberli FR; Jüni P; Räber L; Wenaweser P; Togni M; Billinger M; Tüller D; Seiler C; Roffi M; Corti R; Sütsch G; Maier W; Lüscher T; Hess OM; Egger M; Meier B
N Engl J Med; 2005 Aug; 353(7):653-62. PubMed ID: 16105989
[TBL] [Abstract][Full Text] [Related]
20. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
